Skip to content

Trial Summary

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis



ACTRN/NCT /ethics:


Scientific title:

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeBlood
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-02-18
Anticipated End Date2022-06-22

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorDr Stanley Cheung
Recruitment StatusRecruiting